The first 60 days: Mucinous ovarian cancer
Mucinous ovarian cancer is rare, usually confined to one large ovary at diagnosis and cured by surgery. Its genetics resemble bowel cancer more than ovarian cancer, and pathologists must first rule out a spread from the gut before making the diagnosis. Below, week by week, is what OnCo's record of Mucinous ovarian cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: Early stage, Young women with stage IA disease.
- Medical oncologistNamed in the standard of care for: Early stage, Advanced or recurrent.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Unilateral salpingo-oophorectomy or hysterectomy with staging; appendicectomy if abnormal; chemotherapy usually omitted for stage IA and IB.
Cytoreduction; carboplatin-paclitaxel or gastrointestinal-type capecitabine-oxaliplatin; trastuzumab for HER2-amplified tumours in trials.
Fertility-sparing unilateral salpingo-oophorectomy with staging and close follow-up.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example KRAS mutation, HER2 amplification, CK7 and CK20 pattern and SATB2 to exclude gastrointestinal origin, CEA and CA 19-9 rather than CA-125), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Expansilepattern, Infiltrative pattern, HER2-amplified.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Early stage
- For my situation (early stage), which of the standard options do you recommend and why?Guideline options include: Unilateral salpingo-oophorectomy or hysterectomy with staging; appendicectomy if abnormal; chemotherapy usually omitted for stage IA and IB.
Advanced or recurrent
- For my situation (advanced or recurrent), which of the standard options do you recommend and why?Guideline options include: Cytoreduction; carboplatin-paclitaxel or gastrointestinal-type capecitabine-oxaliplatin; trastuzumab for HER2-amplified tumours in trials.
- Am I a candidate for Capecitabine, Oxaliplatin, Trastuzumab or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Young women with stage IA disease
- For my situation (young women with stage ia disease), which of the standard options do you recommend and why?Guideline options include: Fertility-sparing unilateral salpingo-oophorectomy with staging and close follow-up.
Any stage
- Are there clinical trials I could join, for example of Trastuzumab deruxtecan, HER2?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No proven chemotherapy for advanced disease”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Trials cannot recruit enough patients”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Mucinous ovarian cancer: the full pageMucinous ovarian cancer is rare, usually confined to one large ovary at diagnosis and cured by surgery. Its genetics resemble bowel cancer more than ovarian cancer, and pathologists must first rule out a spread from the gut before making the diagnosis.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.